India Nixes Patents For Allergan Glaucoma Drugs
The country’s Intellectual Property Appellate Board said the patents behind Allergan’s Ganfort and Combigan were invalid as obvious because they didn’t sufficiently innovate from previous discoveries.
The board also found that in registering the patent for Ganfort, Allergan had violated Section 8 of India’s Patent Act, which requires applicants to fully disclose foreign patents.
“In the end, the...
To view the full article, register now.